España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp and dohme de españa, s.a. - desogestrel, etinilestradiol, desogestrel, etinilestradiol, desogestrel, etinilestradiol - excipientes: - anticonceptivos hormonales para uso sistÉmico - progestágenos y estrógenos, preparados secuenciales - desogestrel y estrógeno

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp and dohme de españa, s.a. - desogestrel, etinilestradiol, desogestrel, etinilestradiol, desogestrel, etinilestradiol - excipientes: - anticonceptivos hormonales para uso sistÉmico - progestágenos y estrógenos, preparados secuenciales - desogestrel y estrógeno

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp and dohme de españa, s.a. - mirtazapina - excipientes: - antidepresivos - otros antidepresivos - mirtazapina

Unión Europea - español - EMA (European Medicines Agency)

merck sharp and dohme b.v - posaconazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimicóticos para uso sistémico - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 y 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 y 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refractariedad se define como la progresión de la infección o el fracaso a mejorar después de un mínimo de 7 días antes de la dosis terapéutica de un eficaz tratamiento antifúngico. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 y 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 y 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 y 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refractariedad se define como la progresión de la infección o el fracaso a mejorar después de un mínimo de 7 días antes de la dosis terapéutica de un eficaz tratamiento antifúngico. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 y 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 y 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refractariedad se define como la progresión de la infección o el fracaso a mejorar después de un mínimo de 7 días antes de la dosis terapéutica de un eficaz tratamiento antifúngico. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- la aspergilosis invasiva en pacientes con enfermedad refractaria a la anfotericina b, itraconazol o en pacientes que son intolerantes a estos medicamentos;- fusariosis en pacientes con enfermedad refractaria a la anfotericina b, o en pacientes que son intolerantes a la de la anfotericina b;- chromoblastomycosis y mycetoma en pacientes con enfermedad refractaria a itraconazol o en pacientes que son intolerantes a la de itraconazol;- la coccidioidomicosis en pacientes con enfermedad refractaria a la anfotericina b, itraconazol o fluconazol o en pacientes que son intolerantes a estos medicamentos;- candidiasis orofaríngea: como terapia de primera línea en los pacientes que tienen enfermedad grave o que están inmunocomprometidos, en los que la respuesta a la terapia tópica se espera que para ser pobre. la refractariedad se define como la progresión de la infección o el fracaso a mejorar después de un mínimo de 7 días antes de la dosis terapéutica de un eficaz tratamiento antifúngico. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

merck sharp & dohme corp., una subsidiaria de merck & co., inc., estados unidos - después de la reconstitución, cada dosis de 0.5 ml contiene: virus de la varicela, cepa oka/merck (vivos, atenuados) no menos de 1350 ufp* *ufp: unidades formadoras de placas - polvo y disolvente para suspensiÓn inyectable - después de la reconstitución, cada dosis de 0.5 ml contiene: virus de la varicela, cepa oka/merck (vivos, atenuados) no menos de 1350 ufp* *ufp: unidades formadoras de placas

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp and dohme ltd. - ezetimiba, atorvastatina calcica trihidrato - excipientes: lactosa monohidrato,croscarmelosa sodica,laurilsulfato de sodio,lactosa monohidrato,croscarmelosa sodica,polisorbato 80 - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa en combinación con otros agentes modificadores de lipidos - atorvastatina y ezetimiba

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp and dohme ltd. - ezetimiba, atorvastatina calcica trihidrato - excipientes: lactosa monohidrato,croscarmelosa sodica,laurilsulfato de sodio,lactosa monohidrato,croscarmelosa sodica,polisorbato 80 - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa en combinación con otros agentes modificadores de lipidos - atorvastatina y ezetimiba

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp and dohme ltd. - ezetimiba, atorvastatina calcica trihidrato - excipientes: lactosa monohidrato,croscarmelosa sodica,laurilsulfato de sodio,lactosa monohidrato,croscarmelosa sodica,polisorbato 80 - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa en combinación con otros agentes modificadores de lipidos - atorvastatina y ezetimiba

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp and dohme ltd. - ezetimiba, atorvastatina calcica trihidrato - excipientes: lactosa monohidrato,croscarmelosa sodica,laurilsulfato de sodio,lactosa monohidrato,croscarmelosa sodica,polisorbato 80 - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa en combinación con otros agentes modificadores de lipidos - atorvastatina y ezetimiba

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp and dohme ltd. - ezetimiba, atorvastatina calcica trihidrato - excipientes: lactosa monohidrato,croscarmelosa sodica,laurilsulfato de sodio,lactosa monohidrato,croscarmelosa sodica,polisorbato 80 - agentes modificadores de los lÍpidos, combinaciones - inhibidores de la hmg-coa reductasa en combinación con otros agentes modificadores de lipidos - atorvastatina y ezetimiba